Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (320)	5/8/1999 9:54:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Accretive to Earnings! Mason, <<On the more important front, I have a nagging question about the debt the co. has incurred for the acquisitions over the past year. Doesn't this worry you at all about earnings?>> The company has stated time and time again that all acquisitions "should" be accretive to earnings. I find no evidence that suggests otherwise. My greatest fantasy is that Immucor will be involved in a bidding war between Abbott Laboratories, Biotest, Diamed and Hewlett Packard's new instrumentation spin-off. Other potential suitors include Elmer Perkins, Serologicals, and Johnson & Johnson. This is getting exciting! Best O'Luck! Tom